文献速递垂体与肾上腺疾病

可溶性α-Klotho在肢端肥大症中的应用:与传统疾病活动标志物的比较

Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本研究在2个学术中心回顾性纳入肢端肥大症患者(术前、术后及生长抑素类似物治疗者)、无功能垂体腺瘤患者和健康对照,检测可溶性α-Klotho(sαKL)并与传统标志物比较。sαKL与IGF-I强相关(rs=0.80,P<0.0001), cutoff 1548 pg/mL区分控制与未控制患者的敏感性97.8%、特异性100%。sαKL有助于评估肢端肥大症疾病活动,尤其在GH与IGF-I不一致时。

要点

  • sαKL与IGF-I强相关(rs=0.80,P<0.0001),可反映GH分泌状态。
  • sαKL cutoff 1548 pg/mL区分控制与未控制患者,敏感性97.8%、特异性100%。
  • 在GH与IGF-I不一致时,sαKL检测可能有助于判断疾病活动。

核心结论

  • sαKL可作为评估肢端肥大症疾病活动的生物标志物,与GH分泌状态密切相关,动态范围大且受生物混杂因素影响小。

研究设计与样本

  • 回顾性研究,在2个学术中心纳入肢端肥大症患者(术前29例;术后未治疗控制28例、不一致11例、未控制8例;生长抑素类似物治疗控制17例、不一致11例、未控制5例)、无功能垂体腺瘤20例和健康对照31例。

主要发现

  • sαKL与传统标志物相关,尤其与IGF-I相关(rs=0.80,P<0.0001)。
  • 治疗前sαKL中位数4.04倍正常上限(四分位距2.26-8.08),治疗后控制者和多数不一致患者降至正常。
  • sαKL cutoff 1548 pg/mL区分控制与未控制患者的敏感性97.8%(88.4%-99.9%),特异性100%(77.1%-100%)。
  • 84%的不一致患者sαKL低于cutoff,其余16%尽管随机GH正常但sαKL和IGF-I持续升高。
  • 性别、年龄、BMI及骨钙代谢标志物对sαKL浓度无显著影响。

关键数值与推荐

  • sαKL cutoff 1548 pg/mL用于区分控制与未控制患者,敏感性97.8%(88.4%-99.9%),特异性100%(77.1%-100%)。

临床怎么用

  • 在肢端肥大症中可检测sαKL辅助判断疾病活动,尤其当GH与IGF-I提供不一致信息时。

局限性

  • 回顾性研究,样本量有限,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Soluble alpha klotho (sαKL) has been linked to growth hormone (GH) action, but systematic evaluation and comparisons with traditional biomarkers in acromegaly are lacking. OBJECTIVE: To evaluate the potential of sαKL to aid classification of disease activity. METHODS: This retrospective study at 2 academic centers included acromegaly patients before surgery (A, n = 29); after surgery (controlled, discordant, or uncontrolled) without (B1, B2, B3, n = 28, 11, 8); or with somatostatin analogue treatment (C1, C2, C3, n = 17, 11, 5); nonfunctioning pituitary adenomas (n = 20); and healthy controls (n = 31). sαKL was measured by immunoassay and compared with traditional biomarkers (random and nadir GH, insulin-like growth factor I [IGF-I], IGF binding protein 3). Associations with disease activity were assessed. RESULTS: sαKL was correlated to traditional biomarkers, particularly IGF-I (rs=0.80, P <0.0001). High concentrations before treatment (A, median, interquartile range: 4.04 × upper limit of normal [2.26-8.08]) dropped to normal after treatment in controlled and in most discordant patients. A cutoff of 1548 pg/mL for sαKL discriminated controlled (B1, C1) and uncontrolled (B3, C3) patients with 97.8% (88.4%-99.9%) sensitivity and 100% (77.1%-100%) specificity. sαKL was below the cutoff in 84% of the discordant subjects. In the remaining 16%, elevated sαKL and IGF-I persisted, despite normal random GH. Sex, age, body mass index, and markers of bone and calcium metabolism did not significantly affect sαKL concentrations. CONCLUSION: Our data support sαKL as a biomarker to assess disease activity in acromegaly. sαKL exhibits close association with GH secretory status, large dynamic range, and robustness toward biological confounders. Its measurement could be helpful particularly when GH and IGF-I provide discrepant information.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Schweizer JROL, Schilbach K, Haenelt M, et al. Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity. J Clin Endocrinol Metab. 2021. PMID: 33864468. doi:10.1210/clinem/dgab257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。